Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease

a cardiometabolic disease and desaturase technology, applied in the field of desaturase inhibition of delta6 desaturase for the treatment of cardiometabolic disease, can solve the problems of complex and risky approach, imbalance in the relative distribution of species with different, or even opposing, pathogenic potentials, and the targeting of select aa metabolism enzymes as an anti-inflammatory treatment of metabolic disease and its complications

Inactive Publication Date: 2015-07-02
COLORADO STATE UNIV RES FOUND
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present patent provides a method for identifying a compound that can treat cardiometabolic diseases or disorders in mammals. This is done by testing the effect of the compound on the activity of a specific enzyme called delta-6 desaturase (D6D). The method involves contacting D6D with the compound and measuring its activity level in the presence of the compound. A decrease in D6D activity in the presence of the compound relative to its activity level without the compound identifies the compound as a potential treatment for cardiometabolic diseases or disorders. The method can be performed in a laboratory using mammalian cells or in animal models of human cardiometabolic diseases. The patent also provides a transgenic knock-in mammal that overexpresses D6D and an animal model with a heterozygous promotion of the endogenous gene encoding D6D. Additionally, the patent describes an inhibitor of D6D that can be used to treat cardiometabolic diseases or disorders.

Problems solved by technology

The growing prevalence of obesity and type 2 diabetes complicates risk and clinical management by potentiating and / or exacerbating hypertension, hyperlipidemia, atherosclerosis and cardiomyopathy, leading to increasing use of the term “cardiometabolic disease” (CMD) to encompass the many facets of this complex syndrome.
However, numerous large cohort studies examining the effect of dietary n6 PUFA (LA) intake on insulin sensitivity have produced widely variable results, making unclear whether to increase, decrease, or ignore dietary intake of LA in attempting to manage metabolic risk.
However, there is some concern regarding the use of these and other inhibitors of AA metabolism enzymes, as different selectivities and potencies of an inhibitor for one enzyme pathway may divert AA into another pathway, creating an imbalance in the relative distribution of species with different, or even opposing, pathogenic potentials.
Therefore, the targeting of select AA metabolism enzymes as an anti-inflammatory treatment in metabolic disease and its complications is thought to be a complicated and risky approach.
However, the effectiveness of D6D inhibition at reducing or reversing CMD and related syndromes remains largely unknown.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
  • Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
  • Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Inhibition of D6D Ameliorates Cardiometabolic Disease in Mice

[0083]To assess the effects of D6D inhibition on structures and processes related to cardiometabolic diseases and disorders, the following experiments were conducted. Animal studies have reported evidence of increased D6D activity in rodent models of CMD (e.g., increase in AA / LA in tissue phospholipids), making them reasonable models for studying the role of D6D in its pathogenesis. To probe the effect of D6D directly, the compound SC-26196, a selective D6D inhibitor was orally administered by admixing the SC-26196 in the food mixtures of the rodent models of CMD at a dosage of about 100 mg / kg / day for four weeks. The rodent models of CMD used in these experiments included a murine model of hyperphagic obesity (leptin-deficient ob mice) and a diet-induced insulin resistance model (normal C57Bl / 6 mice fed a high-fat “Western” diet) for 8 weeks prior to participation in any experiments.

[0084]Initially, the effects of D6D inhi...

example 2

Generation of Fads2 Transgenic Mice

[0089]To develop and characterize a transgenic mouse with global over-expression of the D6D gene, Fads2, the following experiments were conducted.

[0090]A full length mouse Fads2 cDNA sequence (1.6 kb) was cloned into the EcoRV and Notl site of the pcDNA-3.1(+) mammalian expression vector as illustrated schematically in FIG. 15. In this vector, Fads2 was placed downstream of a CMV promoter and upstream of a polyadenylation sequence (BGHpa) and neomycin resistant gene. To generate transgenic mice over-expressing Fads2, a purified ˜4.6 kb Nrul / Bst1107I fragment containing the CMV-Fads2 expression cassette, was microinjected into pronuclei of fertilized FVB / N mice.

[0091]Transgenic positive founder mice were identified by Southern blot and PCR amplification of genomic DNA isolated from the tail. An image of a representative Southern blot comparing wild type (WT), transgenic (TG), and a negative control (NEG) is provided in FIG. 16.

[0092]Independent foun...

example 3

Overexpression of D6D Increases Fasting Glucose and Impairs Glucose Tolerance

[0094]To assess the consequences of D6D overexpression in processes and structures related to cardiometabolic disease and disorders, the following experiments were conducted. A line of mice with transgenic overexpression of the D6D gene (fads2) were developed using the methods summarized in Example 2

[0095]Phenotyping studies of the first-fifth generation of fads2-TG mice at 3-4 months of age were performed to characterize a number of structures related to cardiometabolic disease and disorders that may be related to D6D hyperactivity. Corresponding measurements were performed on wild-type (WT) littermates to assess differential effects due to D6D overexpression. As summarized in FIG. 21, fads2 overexpression impaired glucose tolerance, increased AA / LA ratio in serum, liver, heart, and muscle tissues, and increased fads2 mRNA expression to levels comparable to ob mice (ob) or Western diet-induced cardiometabo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Systems and methods for screening whether a candidate compound inhibits delta-6 desaturase activity are disclosed. Also disclosed is a transgenic mammal which overexpresses a gene encoding delta-6 desaturase and an animal model of a cardiometabolic disorder or disease that includes the transgenic mammal. A method of treating a cardiometabolic disorder or disease is also disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional application of U.S. application Ser. No. 13 / 902,435 filed on May 24, 2013 and entitled “Inhibition of Delta-6 Desaturase for the Treatment of Cardiometabolic Disease”, which claims priority to U.S. Provisional Application Ser. No. 61 / 651,369 filed on May 24, 2012 and entitled “Inhibition of Delta-6 Desaturase for the Treatment of Cardiometabolic Disease”, the disclosures of which are hereby incorporated by reference in their entirety.GOVERNMENTAL SUPPORT[0002]This invention was made with government support under Grant No. R21 HL094890 awarded by the National Institutes of Health. The government has certain rights in the invention.FIELD OF THE INVENTION[0003]The present disclosure relates to systems and methods for screening whether a candidate compound inhibits delta-6 desaturase activity.BACKGROUND OF THE INVENTION[0004]The growing prevalence of obesity and type 2 diabetes complicates risk and clinical ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A01K67/027C12N9/02
CPCA01K67/0278C12N9/0071C12Y114/19A01K2267/0306A01K2227/105A01K2217/072A01K67/027G01N33/6893G01N2500/00G01N2800/04G01N2800/32A61K31/496A01K67/0275A01K2267/0362A01K2267/0375C12Q1/26A61K31/00
Inventor CHICCO, ADAM J.
Owner COLORADO STATE UNIV RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com